Table 2.

Overview of phase-III studies in gastric cancer including anti-angiogenic therapy.

Study	Patients	Region of Recruitment	Treatment	Previous Therapy	Median Overall Survival	Progression-Free Survival
Ohtsu et al. (AVAGAST) 2011 [114]	n = 774 Unresectable locally advanced/metastatic gastric cancer	Asia-Pacific region: 49% Europe: 32% Pan-America: 19%	Bevacizumab + Fluoropyrimidin/Cisplatin vs. Placebo + Fluoropyrimidin/Cisplatin	1st line	12.1 vs. 10.8 months (p = 0.1)	6.7 vs. 5.3 months (p = 0.0037)
Shen et al. [AVATAR] 2015 [115]	n = 202 Unresectable locally advanced/metastatic gastric cancer	China: 100%	Bevacizumab + Capecitabine/Cisplatin vs. Placebo + Capecitabine/Cisplatin	1st line	10.5 vs. 11.4 months (p = 0.56)	6.3 vs. 6.0 months (p = 0.47)
Fuchs et al. [REGARD] 2014 [20]	n = 355 Unresectable or metastastic, locally recurrent gastric or GE junction adenocarcinoma	North America, Europe, Australia: 69% Asia: 8% South/Central America, India, Middle East: 23%	Ramucirumab vs. Placebo	2nd line	5.2 vs. 3.8 months (p = 0.047)	2.1 vs. 1.3 months (p = 0.001)
Wilke et al. [RAINBOW] 2014 [113]	n = 665 Unresectable or metastastic gastric or GE junction adenocarcinoma	Europe, Australia, USA: 60% South/Central America: 7% Asia: 33%	Ramucirumab + Paclitaxel vs. Placebo + Paclitaxel	2nd line	9.6 vs. 7.4 months (p = 0.017)	4.4 vs. 2.9 months (p < 0.0001)
Li et al. 2016 [116]	n = 267 advanced or metastatic gastric or gastroesophageal junction adenocarcinoma	Asia: 100%	Apatinib vs. Placebo	3rd line	6.7 vs. 4.9 months (p = 0.149)	2.6 vs. 1.8 months (p = 0.001)
Cunningham et al. [ST03] 2017 [117]	n = 1063 Resectable adenocarcinoma of the stomach/GE junction/lower esophageus	Europe: 100%	Bevacizumab + epirubicine/capecitabine/cisplatin vs. Placebo + epirubicine/capecitabine/cisplatin	perioperative	3-year-OS:* 48.1 vs. 50.3% (p = 0.36)	No concrete time reported: HR: 1.05 (95% CI: 0.89–1.23); p = 0.56

* Highlighted, as it is different than the median over survival as stated in the header of the column.